Mitoxantrone, Etoposide, and Cytarabine With or Without Valspodar in Patients With Relapsed or Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome: A Phase III Trial (E2995)

PURPOSE: To determine whether adding the multidrug resistance gene-1 (MDR-1) modulator valspodar (PSC 833; Novartis Pharmaceuticals, Hanover, NJ) to chemotherapy provided clinical benefit to patients with poor-risk acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). PATIENTS A...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Clin Oncol
Egile Nagusiak: Greenberg, Peter L., Lee, Sandra J., Advani, Ranjana, Tallman, Martin S., Sikic, Branimir I., Letendre, Louis, Dugan, Kathleen, Lum, Bert, Chin, David L., Dewald, Gordon, Paietta, Elisabeth, Bennett, John M., Rowe, Jacob M.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2004
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5457168/
https://ncbi.nlm.nih.gov/pubmed/15020609
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2004.07.048
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak